Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Vascular Microenvironment, Tumor Immunity and Immunotherapy

Frontiers in Immunology(2021)10.3389/fimmu.2021.811485Source: DataRank Database

Vascular Microenvironment, Tumor Immunity and Immunotherapy is a research paper published in Frontiers in Immunology (2021). On theSindex it has a DataRank of 2.4. It has been cited 134 times, with 103 citing works in its 1-hop citation network.

N/A

2.4DataRank · unranked

Scored on demand from live citation data

Open Access134 citations · 103 citing works in its network

Download PDF

Cite:

Linked data & code

doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (10 grants)OA: goldTopics (34)Linked Datasets (25)DataCite Reuse (25)IDs (PubMed, PMC)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 30%Citation Network 70%

Base Score Contribution

0.736

From this paper's citation signal

Citation Network Contribution

1.7

From 79 citing papers with measurable signal

Learn more about DataRank methodology →

Top 5 citers driving the network score

Ranked by each citer's contribution to N(p) — log1p(C_q) divided by its reference count — out of 103 citers.

Microbubbles-assisted ultrasonication to promote tumor accumulation of therapeutics and modulation of tumor microenvironment for enhanced cancer treatments
Biomaterials202323 citations34 referencesContributes 0.093
Bubble cloud-mediated cavitation for tumor mechanical ablation and effector immune cell deployment
Ultrasonics Sonochemistry202512 citations31 referencesContributes 0.083
Analysis of the immune-inflammatory indices for patients with metastatic hormone-sensitive and castration-resistant prostate cancer
BMC Cancer202412 citations32 referencesContributes 0.080
The cuproptosis-associated 13 gene signature as a robust predictor for outcome and response to immune- and targeted-therapies in clear cell renal cell carcinoma
Frontiers in Immunology202234 citations54 referencesContributes 0.066
Vascular normalization and immunotherapy: Spawning a virtuous cycle
Frontiers in Oncology202223 citations50 referencesContributes 0.064

Authors (2)

Yi Fan ORCID,Zachary L Lamplugh ORCID

Live enrichment

PubMed:34987525 PMC:PMC8720970

National Institute of Neurological Disorders and Stroke

Grant: R01NS094533, R01NS106108

NCI NIH HHS

Grant: R01 CA241501

NIGMS NIH HHS

Grant: T32 GM008076

NINDS NIH HHS

Grant: R01 NS094533

NINDS NIH HHS

Grant: R01 NS106108

National Institutes of Health

Grant: 5R01NS094533-07

Endothelial plasticity in glioma vascularization and therapy resistance

National Institutes of Health

Grant: 5T32GM008076-12

PREDOCTORAL TRAINING PROGRAM IN PHARMACOLOGY

National Institutes of Health

Grant: 5R01CA241501-05

Dissecting the biology and consequence of circulating glioma cells

National Institutes of Health

Grant: 5R01NS106108-05

Macrophage polarization in glioma microenvironment

National Institute of General Medical Sciences

goldLicense: cc-by

publisherhttps://www.frontiersin.org/articles/10.3389/fimmu.2021.811485/pdf

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/8720970

repositoryhttps://doaj.org/article/291b8b97d92540e0883c6e51cefdfc5b

Europe_PMChttps://europepmc.org/articles/PMC8720970

Europe_PMChttps://europepmc.org/articles/PMC8720970?pdf=render

Fields of Study

0301 basic medicine03 medical and health sciences0302 clinical medicine

MeSH Terms

Endothelium, VascularT-LymphocytesLymphocytes, Tumor-InfiltratingAnimalsHumansNeoplasmsNeovascularization, PathologicImmunotherapyImmune ToleranceTumor EscapeTumor Microenvironment

Keywords

T cellsImmunotherapyImmunityInfiltrationimmune suppressionEndothelial CellsTumor MicroenvironmentExhaustionNeovascularization, PathologicT-LymphocytesImmunologyRC581-607Lymphocytes, Tumor-InfiltratingNeoplasmsImmune ToleranceAnimalsHumansTumor EscapeEndothelium, VascularImmunologic diseases. Allergy

Sustainable Development Goals

SDG 3: 3. Good health

Additional file 1 of Analysis of the immune-inflammatory indices for patients with metastatic hormone-sensitive and castration-resistant prostate cancer

10.6084/m9.figshare.26211341.v1figshare

Additional file 1 of Analysis of the immune-inflammatory indices for patients with metastatic hormone-sensitive and castration-resistant prostate cancer

10.6084/m9.figshare.26211341figshare

Additional file 2 of Analysis of the immune-inflammatory indices for patients with metastatic hormone-sensitive and castration-resistant prostate cancer

10.6084/m9.figshare.26211676.v1figshare

Additional file 2 of Analysis of the immune-inflammatory indices for patients with metastatic hormone-sensitive and castration-resistant prostate cancer

10.6084/m9.figshare.26211676figshare

Additional file 3 of Analysis of the immune-inflammatory indices for patients with metastatic hormone-sensitive and castration-resistant prostate cancer

10.6084/m9.figshare.26746823.v1figshare

Additional file 3 of Analysis of the immune-inflammatory indices for patients with metastatic hormone-sensitive and castration-resistant prostate cancer

10.6084/m9.figshare.26746823figshare

Additional file 4 of Analysis of the immune-inflammatory indices for patients with metastatic hormone-sensitive and castration-resistant prostate cancer

10.6084/m9.figshare.26746826.v1figshare

Additional file 4 of Analysis of the immune-inflammatory indices for patients with metastatic hormone-sensitive and castration-resistant prostate cancer

10.6084/m9.figshare.26746826figshare

Additional file 5 of Analysis of the immune-inflammatory indices for patients with metastatic hormone-sensitive and castration-resistant prostate cancer

10.6084/m9.figshare.26746829.v1figshare

Additional file 5 of Analysis of the immune-inflammatory indices for patients with metastatic hormone-sensitive and castration-resistant prostate cancer

10.6084/m9.figshare.26746829figshare

Additional file 6 of Analysis of the immune-inflammatory indices for patients with metastatic hormone-sensitive and castration-resistant prostate cancer

10.6084/m9.figshare.26746832.v1figshare

Additional file 6 of Analysis of the immune-inflammatory indices for patients with metastatic hormone-sensitive and castration-resistant prostate cancer

10.6084/m9.figshare.26746832figshare

Additional file 7 of Analysis of the immune-inflammatory indices for patients with metastatic hormone-sensitive and castration-resistant prostate cancer

10.6084/m9.figshare.26746835.v1figshare

Additional file 7 of Analysis of the immune-inflammatory indices for patients with metastatic hormone-sensitive and castration-resistant prostate cancer

10.6084/m9.figshare.26746835figshare

Additional file 8 of Analysis of the immune-inflammatory indices for patients with metastatic hormone-sensitive and castration-resistant prostate cancer

10.6084/m9.figshare.26746838.v1figshare

Additional file 8 of Analysis of the immune-inflammatory indices for patients with metastatic hormone-sensitive and castration-resistant prostate cancer

10.6084/m9.figshare.26746838figshare

Additional file 9 of Analysis of the immune-inflammatory indices for patients with metastatic hormone-sensitive and castration-resistant prostate cancer

10.6084/m9.figshare.26746841.v1figshare

Additional file 9 of Analysis of the immune-inflammatory indices for patients with metastatic hormone-sensitive and castration-resistant prostate cancer

10.6084/m9.figshare.26746841figshare

Additional file 10 of Analysis of the immune-inflammatory indices for patients with metastatic hormone-sensitive and castration-resistant prostate cancer

10.6084/m9.figshare.26746844.v1figshare

Additional file 10 of Analysis of the immune-inflammatory indices for patients with metastatic hormone-sensitive and castration-resistant prostate cancer

10.6084/m9.figshare.26746844figshare